Multicenter study of Genome-Wide Association Study (GWAS) concerning of the efficacy of tolvaptan. - Effect of tolvaptan on refractory ascites.

The third department of internal medicine, Nara Medical University0 sites300 target enrollmentFebruary 1, 2017

Overview

No summary available.

Registry

who.int

Start Date

February 1, 2017

End Date

March 31, 2020

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

The third department of internal medicine, Nara Medical University

•1\) Adequate cardiac organ function a) Patients with conjestive heart failure above NYHA class3 b) Patients with severe hypertension 2\) Patients with severe and active infectious disease (exclude HBV,HCV hepatitis) 3\) Patients with HIV 4\) Patients taking dialysis 5\) Patients with portal tumor thrombosis (Vp3 or Vp4\) 6\) Patients with hepatic encephalopathy 7\) Patients with crutial digestive bleedings within 4 weeks 8\) Patients with the following treatment a) Systemic chemotherapy b) Being treated with invasive surgical therapy within 4 weeks 9\) Patients with oral intake difficulty 10\)Patients with severe digestive diseases 11\)Patients taking a tablet which would affect this clinical study 12\)Pregnant woman, lactating woman, or a woman suspected of pregnancy 13\)Patients with severe allergic reaction to Tolvaptan 14\)Patients with drug abuse or psycological disorders 15\) Patients concluded to be inappropriate to participate in this study by their physitians